AIRLINK 196.20 Increased By ▲ 4.36 (2.27%)
BOP 10.16 Increased By ▲ 0.29 (2.94%)
CNERGY 7.92 Increased By ▲ 0.25 (3.26%)
FCCL 38.30 Increased By ▲ 0.44 (1.16%)
FFL 15.90 Increased By ▲ 0.14 (0.89%)
FLYNG 25.44 Increased By ▲ 0.13 (0.51%)
HUBC 130.65 Increased By ▲ 0.48 (0.37%)
HUMNL 13.79 Increased By ▲ 0.20 (1.47%)
KEL 4.66 Decreased By ▼ -0.01 (-0.21%)
KOSM 6.38 Increased By ▲ 0.17 (2.74%)
MLCF 44.95 Increased By ▲ 0.66 (1.49%)
OGDC 209.79 Increased By ▲ 2.92 (1.41%)
PACE 6.68 Increased By ▲ 0.12 (1.83%)
PAEL 41.05 Increased By ▲ 0.50 (1.23%)
PIAHCLA 17.75 Increased By ▲ 0.16 (0.91%)
PIBTL 8.13 Increased By ▲ 0.06 (0.74%)
POWER 9.38 Increased By ▲ 0.14 (1.52%)
PPL 180.99 Increased By ▲ 2.43 (1.36%)
PRL 40.00 Increased By ▲ 0.92 (2.35%)
PTC 24.41 Increased By ▲ 0.27 (1.12%)
SEARL 111.75 Increased By ▲ 3.90 (3.62%)
SILK 0.99 Increased By ▲ 0.02 (2.06%)
SSGC 38.17 Decreased By ▼ -0.94 (-2.4%)
SYM 19.22 Increased By ▲ 0.10 (0.52%)
TELE 8.75 Increased By ▲ 0.15 (1.74%)
TPLP 12.10 Decreased By ▼ -0.27 (-2.18%)
TRG 66.00 Decreased By ▼ -0.01 (-0.02%)
WAVESAPP 12.29 Decreased By ▼ -0.49 (-3.83%)
WTL 1.69 Decreased By ▼ -0.01 (-0.59%)
YOUW 3.99 Increased By ▲ 0.04 (1.01%)
BR100 12,090 Increased By 159.6 (1.34%)
BR30 35,982 Increased By 322.6 (0.9%)
KSE100 114,866 Increased By 1659.2 (1.47%)
KSE30 36,099 Increased By 534 (1.5%)
Pakistan

DRAP grants permission to another Chinese firm to conduct clinical trials of COVID vaccine

  • Anhui Zhifei longcom will conduct its trials in Karachi at a private hospital, while in Lahore at the University of Health Sciences and another private health facility
  • At least 9,000 volunteers will participate in clinical trials of the Anhui Zhifei vaccine across the country
Published February 14, 2021

(Karachi) The Drug Regulatory Authority of Pakistan (DRAP) has granted permission to a Chinese company for third phase clinical trials of its Covid-19 vaccine in the country, local media reported on Sunday.

The clinical trials committee of the Drug Regulatory Authority of Pakistan (DRAP) has granted permission to China’s Anhui Zhifei longcom for clinical trials of its vaccine. The approval has been granted after China’s bio-pharmaceutical company, Anhui Zhifei sought permission for clinical trials in Pakistan in December 2020.

The Chinese pharma company initially, will conduct third phase clinical trials of its Covid-19 vaccine candidate in Karachi and Lahore.

Anhui Zhifei longcom will conduct its vaccine’s clinical trials in Karachi at a private hospital, while in Lahore at the University of Health Sciences and another private health facility.

At least 9,000 volunteers will participate in clinical trials of the Anhui Zhifei vaccine across the country.

Anhui Zhifei had prepared its Covid vaccine in May 2020 under the aegis of the Chinese Company of Sciences. The company had conducted the phase I and phase II trials in June 2020, in which the vaccine was found safe and effective against the disease.

Around 29,000 volunteers are participating in third phase of the clinical trials of the vaccine in different countries. After Can Sino Bio, Anhui Zhifei has been second Chinese company holding trials of its vaccine in Pakistan.

Comments

Comments are closed.